Analysis: The drug buoyed by patient power
The clamour for a Roche breast-cancer drug reached fever pitch last week. Ian Hall asks what PROs can learn from Herceptin’s stint in the media spotlight
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>